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Ischaemia/reperfusion cardiac injury contributes to morbidity and mortality during percutaneous coronary 
intervention, heart surgery and transplantation. Even when the recanalization of an infarct-related coronary 
artery is carried out successfully, there is still a risk of death due to reperfusion injury. Numerous pharmacological 
interventions have been found in experiments on animals. However, the translation of these interventions 
to clinical practice has been disappointing. None of the drug treatment has been able to improve in-hospital 
mortality of patients with acute myocardial infarction. The search for pharmacological agents able to salvage 
myocardium during reperfusion continues. Opioid receptor (OR) agonists represent one of the promising group 
of drugs for treatment of patients with myocardial infarction. It has been found that µ-, δ- and κ-OR agonists are 
able to attenuate heart injury when administered before or at the beginning of reperfusion. However, what kind 
of OR receptors need to be activated in order to protect the heart during reperfusion and the precise mechanism 
of this effect have yet to be elucidated.




РАЗРАБОТКА ТКАНЕИНЖЕНЕРНОГО СОСУДИСТОГО ГРАФТА МАЛОГО ДИАМЕТРА 
ДЛЯ НУЖД СЕРДЕЧНО-СОСУДИСТОЙ ХИРУРГИИ
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НИИ КПССЗ имеет большой опыт в разработке изделий для сердечно-сосудистой хирургии, в частности биопротезов кла-
панов сердца и сосудов. С 2010 года под руководством академика РАН л. С. Барбараша начаты исследования по созданию био-
резорбируемых сосудистых протезов малого диаметра. Основная цель – создание полимерных конструкций с бионаправленным 
действием, способных заменить отдельные структуры живого организма, в частности сердечно-сосудистой системы. Научная но-
визна поставленной задачи заключается в использовании нового подхода создания органа непосредственно в организме пациента 
за счет биофункциональности и биорезорбируемости полимерных конструкций. доказана долгосрочная проходимость полимерных 
сосудистых графтов на основе поликапролактона и композиции полигидроксибутирата/валерата и поликапролактона. В экспери-
ментах in vitro доказано, что ростовые факторы, инкорпорируемые в состав биодеградируемых графтов, сохраняют свою био-
логическую активность. В долгосрочных экспериментах in vivo доказано, что сосудистый эндотелиальный фактор роста ускоряет 
эндотелизацию и улучшает проходимость биодеградируемых полимерных сосудистых графтов. 
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RICICd has large experience in the development of products for cardiovascular surgery, in particular, the bioprosthesis heart valves 
and blood vessels. Since 2010, under the leadership of the academician of RAS L. S. Barbarash researches to create bioresorbable 
vascular prostheses of small diameter began. the primary purpose – to create polymer structures with bio-directed action capable to 
replace individual structures of a living organism, in particular, of cardiovascular system. Scientific novelty of the problem lies in using a new 
approach for creation an organ directly in the patient’s body by biofunctional and bioresorbable features of polymer structures. the long-term 
patency of PCL vascular grafts and PHBV and PCL composition grafts had proved. the in vitro experiments had proved that growth factors 
incorporated into composition of biodegradable grafts retain their biological activity. the long-term in vivo experiments had demonstrated 
that vascular endothelial growth factor had accelerated endothelization and had improved vascular patency of biodegradable polymer grafts.
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НИИ КПССЗ имеет большой опыт в разработ-
ке изделий для сердечно-сосудистой хирургии, 
в частности биопротезов клапанов сердца и сосу-
дов. Разработка биологических протезов клапана 
сердца, сосудов и ксеноперикардиальных лоску-
тов для интра- и ангиопластики в организации ве-
дется с 1994 года. Разработаны методы консерва-
ции биоматериалов с применением эпоксисоеди-
нений, а также различные технологии повышения 
как гемосовместимости биоматериала, так и био-
совместимости в целом [1]. 
С учетом того, что НИИ КПССЗ является од-
ним из ведущих кардиохирургических центров 
России, выполняющих операции аортокоронар-
ного шунтирования, и вследствие отсутствия на 
рынке сосудистых имплантатов, пригодных для 
аортокоронарного шунтирования, в 2010 году под 
руководством академика РАН Л. С. Барбараша на-
чаты исследования по созданию биорезорбируе-
мых сосудистых протезов малого диаметра. Наша 
команда уже несколько лет изучает проблему 
взаимодействия организма с биосовместимыми 
биорезорбируемыми полимерами на клеточном 
и тканевом уровне [2, 3, 4]. Данная работа ведется 
с целью создания полимерных конструкций с био-
направленным действием, способных заменить 
отдельные структуры живого организма, в част-
ности, сердечно-сосудистой системы. Научная 
ФУНДАМЕНТАЛЬНЫЕ АСПЕКТЫ 
СЕРДЕЧНО-СОСУДИСТОЙ ХИРУРГИИ
FUNDAMENTAL ASPECTS OF CARDIOVASCULAR SURGERY
The attempts to salvage myocardium 
during reperfusion using pharmacological 
interventions
It is commonly accepted that the only effective 
treatment of myocardial infarction is recanalization 
of the infarct-related coronary artery. This can be 
achieved by thrombolysis, percutaneous coronary 
interventi n (PCI), o  coro ary artery bypass grafting 
[1-3]. Unfortunately, there is always a risk of death 
for patients with myocardial infarction, even when 
the recanalization of the coronary artery is carried 
out fast and successfully [4]. Therefore, there is a 
pressing need for creation of new generation drugs 
able to prevent reperfusion heart injury. 
Nowadays, no drug is available, which would 
be able to attenuate effectively the area of necrosis 
and mortality in patients with acute myocardial 
infarction. Different pharmaceutical companies 
and scientific laboratories carry out the search 
for this kind of medicine. However, until now, no 
breakthrough has been achieved in this area.  
A number of drugs have been clinically tested 
for reperfusion injury. For example, it has been 
proposed that the calcium sensitizer levosimendan 
has a potential to reduce infarct size. The 
randomized double-blind clinical study showed 
improvement of hemodynamic function in patients 
with ST-elevation myocardial infarction (STEMI) 
treated by PCI. However, no infarct-limiting effect 
of levosimendan was found [5]. Inhibitors of 
Na+/H+ exchanger that showed cardioprotective 
properti s in animal m dels [6] failed to protect 
heart in clinical settings [7] and even demonstrated 
increased mortality [8]. The gold standard MPTP 
inhibitor cyclosporine A, which showed infarct-
li iting effect in laboratory experiments [9-11], 
did not reduc  the risk of the composite outcome 
of death from any cause, worsening of heart failure 
during the initial hospitalization/rehospitalization, 
or causing adverse left ventricular remodelling in 
patients with STEMI [12]. The P2Y12 receptor 
inhibitor clopidogrel appeared to reduce infarct size 
in patients with acute myocardial ischemia [13, 14], 
but had no effect on mortality in patients with this 
kind of pathology [15]. A statin atorvastatin neither 
improved left ventricular function, nor reduced 
infarct size in STEMI patients [16-18]. Intravenous 
adenosine infusion has been found to reduce infarct 
size and attenuate the No Reflow phenomenon in 
STEMI patients [19-22]. However, as Cohen M.V. 
and Downey J.M. [23] have pointed out, the ability 
of adenosine administered at or shortly before 
reperfusion to provide cardioprotection against 
infarction is indeed quite controversial. The authors 
noted that cardioprotective effect of the intravenous 
infusion of adenosine occurred when it was used 
as a form of preconditioning, prior to ischemia, 
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whilst given at reperfusion, adenosine simply did 
not protect the heart. The infarct-limiting effect of a 
piperazine derivative trimetazidine is also debatable 
[24, 25]. In general, the drugs mentioned above 
showed cardioprotective effects in experiments on 
animal models or in patients when administered 
prior to recanalization of the infarct-related coronary 
artery, but were ineffective in clinical settings when 
introduced during reperfusion. Furthermore, none of 
these medicines could improve in-hospital mortality 
of patients with STEMI. 
Clinical relevance of the use of a cardioprotective 
agent prior to ischemia is restricted to cardiac 
surgery, when ischemia is caused by aortic cross-
clamping. However, in most cases, it is impossible to 
predict an incident of acute myocardial ischemia and 
carry out the treatment prior to the ischemic event. 
A possibility to attenuate specifically the reperfusion 
heart injury had been unclear until the discovery of 
the phenomenon of ischemic postconditioning in 
2003 [26]. The authors demonstrated that a few brief 
(30 sec each) episodes of ischemia and reperfusion 
produced at the commencement of reperfusion 
following prolonged ischemia halved infarct size. 
Based on these data, many scientist are trying to 
find the way to salvage the myocardium during 
reperfusion by treating the heart not before ischemia, 
but just before or during reperfusion. In this context, 
opioid receptor (OR) agonists represent a promising 
group of drugs. 
Opioid receptors as novel targets for prevention 
of reperfusion heart injury
It has been shown [27-29] that OR agonists 
reduce infarct size when administered before the 
onset of reperfusion. Thus in 2004, Gross E.R. 
et al. [29] found that intravenous infusion of a 
preferential µ-OR morphine or δ-OR agonist 
BW373U86 (1mg/kg) 5 min prior to reperfusion in 
rats promotes decrease in infarct size-to-area at risk 
ratio (IS/AAR). These results are consistent with 
a recent study indicating that the selective µ-OR 
agonist endomorphine-1 (50 µg/kg) reduced infarct 
size when injected intravenously 5 min before 
reperfusion [30]. Infarct-limiting effect of morphine 
during reperfusion has also been confirmed by Gong 
et al. [27]. Intravenous injection of the selective 
κ1-OR agonist U-50,488 (0.1 mg/kg) 5 min before 
reperfusion reduced IS/AAR [28]. This effect was 
abolished by the inhibition of κ1-OR with nor-
binaltorphimine.
The precise mechanism of the cardioprotective 
effect of the OR agonists during reperfusion has yet to 
be discovered. However, it has been established that 
ORs represent Gi/o-coupled receptors that inhibit 
adenylyl cyclase and activate phospholipase C, which 
in turn, synthesizes diacylglycerols stimulating 
protein kinase C (PKC) [31]. This was confirmed by 
the work of Peart J.N. & Gross G.J. They showed 
in the experiments on isolated perfused murine heart 
that pertussis toxin, which rybosylates the αi subunit 
of the Gi/o protein, eliminated the cardioprotective 
effect of morphine [32]. Currently it is suggested 
that Gi/o proteins serve as an intermediary link 
between ORs and the protein kinases that perform 
the protective signaling [33]. The following kinases 
may be involved in the cardioprotective mechanism 
of the ORs/ Gi/o activation: PKC [32, 33]; PI3 
kinase, Akt, and MAPK – the RISK pathway [34, 
35]; GSK-3β and JAK2 [36]. The endothelial nitric 
oxide synthase (eNOS) has been implicated in the 
preconditioning-induced triggering of Gi/o coupled 
receptors/PKC pathway [37] and could be involved 
in the protective effect of ORs [38]. Redox signaling 
has also been found to participate in the effects of 
ORs [39]. The studies have also indicated that 
these effects of OR agonists result in inhibition of 
mitochondrial permeability transition pore opening 
[33], which are critical in reperfusion-induced heart 
injury [40].
Taken together, it is of paramount importance to 
find a pharmacological intervention able to salvage 
myocardium during reperfusion and OR agonist 
represent a perspective group of drugs in this respect. 
Further studies are needed in order to establish what 
kind of ORs need to be activated to achieve the 
optimal heart salvation during reperfusion and the 
mechanism involved.    
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